Dan Leonard
Stock Analyst at UBS
(3.76)
# 680
Out of 5,179 analysts
307
Total ratings
50.56%
Success rate
6.91%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $180 → $165 | $110.24 | +49.67% | 24 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Buy | $200 → $195 | $110.12 | +77.08% | 2 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $170 → $175 | $159.16 | +9.95% | 7 | Feb 25, 2026 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $20 | $19.48 | +2.67% | 8 | Feb 20, 2026 | |
| WAT Waters | Maintains: Neutral | $395 → $370 | $289.16 | +27.96% | 13 | Feb 10, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $280 → $240 | $163.85 | +46.48% | 19 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $79 | $50.95 | +55.05% | 13 | Feb 5, 2026 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $33.72 | +27.52% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $84.61 | +30.01% | 11 | Oct 30, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $473.36 | +24.64% | 18 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.75 | +160.87% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $300 → $305 | $451.20 | -32.40% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $181.52 | +23.95% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,232.04 | +9.57% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $265.40 | +16.80% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $267.02 | +16.10% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $83.90 | +37.07% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $90.51 | +9.38% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $7.41 | +237.38% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $7.82 | +15.09% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $15.59 | +124.50% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $117.67 | +69.97% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.86 | +284.62% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $182.65 | -61.68% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $12.41 | -43.59% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $102.08 | +154.70% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $195.51 | -25.84% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $75.67 | +18.94% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $59 → $61 | $39.07 | +55.16% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $264.20 | +28.69% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $13.43 | +78.70% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $4.28 | +717.76% | 12 | Aug 14, 2019 |
Agilent Technologies
Feb 26, 2026
Maintains: Buy
Price Target: $180 → $165
Current: $110.24
Upside: +49.67%
Repligen
Feb 25, 2026
Maintains: Buy
Price Target: $200 → $195
Current: $110.12
Upside: +77.08%
Charles River Laboratories International
Feb 25, 2026
Maintains: Neutral
Price Target: $170 → $175
Current: $159.16
Upside: +9.95%
10x Genomics
Feb 20, 2026
Maintains: Neutral
Price Target: $14 → $20
Current: $19.48
Upside: +2.67%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $395 → $370
Current: $289.16
Upside: +27.96%
IQVIA Holdings
Feb 6, 2026
Maintains: Buy
Price Target: $280 → $240
Current: $163.85
Upside: +46.48%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $79
Current: $50.95
Upside: +55.05%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $33.72
Upside: +27.52%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $84.61
Upside: +30.01%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $473.36
Upside: +24.64%
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $5.75
Upside: +160.87%
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $451.20
Upside: -32.40%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $181.52
Upside: +23.95%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,232.04
Upside: +9.57%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $265.40
Upside: +16.80%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $267.02
Upside: +16.10%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $83.90
Upside: +37.07%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $90.51
Upside: +9.38%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $7.41
Upside: +237.38%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $7.82
Upside: +15.09%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $15.59
Upside: +124.50%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $117.67
Upside: +69.97%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.86
Upside: +284.62%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $182.65
Upside: -61.68%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $12.41
Upside: -43.59%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $102.08
Upside: +154.70%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $195.51
Upside: -25.84%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $75.67
Upside: +18.94%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $59 → $61
Current: $39.07
Upside: +55.16%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $264.20
Upside: +28.69%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $13.43
Upside: +78.70%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $4.28
Upside: +717.76%